SLU-PP-332 – 1.5mg (3ml Pen)

SLU-PP-332 is a synthetic agonist of the estrogen-related receptor family, a group of orphan nuclear receptors central to oxidative metabolism. Research interest stems from the observation that these receptors sit upstream of the transcriptional programmes governing mitochondrial biogenesis and fuel selection. The compound is recent, entirely preclinical, and its literature is dominated by the group that developed it.

SLU-PP-332 is reported to act as a pan-agonist at estrogen-related receptors alpha, beta and gamma. These receptors function as transcriptional regulators of genes governing oxidative phosphorylation, fatty acid oxidation and mitochondrial biogenesis, working in concert with PGC-1alpha. Research in skeletal muscle models describes upregulation of oxidative gene programmes and increased fatty acid utilisation, with reported changes in exercise capacity in rodent studies. The compound is a small molecule rather than a peptide and its pharmacokinetic profile is not well characterised.

A very small and recent literature confined to rodent and cell models, produced largely by a single research group. Independent replication is limited and no human data exist.

Receptor pharmacology

Characterisation of pan-ERR agonism and selectivity profiling.

Skeletal muscle research

Rodent studies on oxidative gene expression and mitochondrial content.

Exercise capacity

Preclinical work reporting changes in endurance performance in mice.

Metabolic models

Investigation of fuel selection and fatty acid oxidation in diet-induced obesity models.

Evidence maturity

Early-stage compound with no independent human characterisation.